This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Best And Worst FDA Drug Approval Stocks of 2013

BOSTON ( TheStreet) -- Bad news from Europe is in store for Arena Pharmaceuticals (ARNA - Get Report) . FDA advisory panels will deal harshly with Delcath Systems (DCTH - Get Report) and Aveo Pharmaceuticals (AVEO - Get Report). An early approval filing in the cards for Sarepta Therapeutics (SRPT - Get Report); and Ziopharm Oncology's (ZIOP - Get Report) sarcoma drug emerges as a winner. These are some of the predictions made by investors who submitted entries to TheStreet's latest FDA Drug Approval Contest.

I hesitate to call these picks "consensus," but 113 entries are a decent sample size from which to gauge retail investor sentiment. Accuracy can also be hit and miss. The crowd participating in my previous two FDA approval contests was correct collectively 80% and 57% of the time.

I crunched the numbers. Here are your predictions:

Sarepta Therapeutics: 55% of investors believe FDA will grant permission to seek accelerated approval for eteplirsen. Forty-five percent predict no accelerated approval. There isn't much daylight between those two numbers. I've written previously about Wall Street investors leaning more bearish on the accelerated approval decision; so it doesn't surprise me to see a more bullish stance taken by retail investors, even if just a slight one.

Arena Pharmaceuticals: Investors who entered my contest take a dim view of Belviq's approval prospects in Europe. The margin was huge: 76% predict European regulators reject the weight-loss pill while only 24% say it will be approved. Areniacs like to shout "Idiot!" (or worse) at anyone who dares to suggest European regulators will be less than sanguine with Belviq's mediocre efficacy and still-unanswered questions about its long-term safety. Surprise, it's the Areniacs who are in the minority.

Titan Pharmaceuticals (TTNP): Seventy-two percent of respondents predict a recommendation favoring Probuphine's approval by an FDA advisory panel. Twenty-eight percent say the panel will vote against the implantable formulation of buprenorphine.

A.P. Pharma (APPA): FDA approval of APF530: 63%. Rejection: 37%.

Biogen Idec (BIIB): FDA approval of BG-12: 87%. Rejection: 13%

United Therapeutics (UTHR): FDA approval of oral Remodulin: 60%. Rejection: 40%. This is another relatively close call. FDA appeared to come down hard on oral Remodulin when the drug was rejected last year, but then regulators granted United Therapeutics a surprisingly short review period after the drug was resubmitted (without new clinical data.)
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ZIOP $13.36 0.00%
ARNA $4.04 0.00%
AVEO $1.41 0.00%
DCTH $0.54 0.00%
SRPT $31.92 0.00%

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs